#
Timoptic Ocumeter Plus
  • Drugs A to Z
  • Timoptic Ocumeter Plus (Ophthalmic)

Timoptic Ocumeter Plus (Ophthalmic)

Generic name:timolol (ophthalmic route) [ TIM-oh-lol ]
Drug class:Ophthalmic glaucoma agents

Medically reviewed by Drugs.com. Last updated on Jan 29, 2022.

Commonly used brand name(s)

In the U.S.

  • Betimol
  • Istalol
  • Timoptic Ocudose
  • Timoptic Ocumeter
  • Timoptic Ocumeter Plus
  • Timoptic-XE Ocumeter
  • Timoptic-XE Ocumeter Plus

Available Dosage Forms:

  • Solution
  • Gel Forming Solution

Therapeutic Class: Antiglaucoma

Pharmacologic Class: Beta-Adrenergic Blocker, Nonselective

Uses for Timoptic Ocumeter Plus

Timolol eye drops is used alone or together with other medicines to treat increased pressure in the eye that is caused by open-angle glaucoma or a condition called ocular (eye) hypertension. This medicine is a beta-blocker.

Timolol (Timoptic® in Ocudose®) may be used when you are sensitive to the preservative in Timoptic®, benzalkonium chloride, or when you need a preservative free eye drops.

This medicine is available only with your doctor's prescription.

Before using Timoptic Ocumeter Plus

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of timolol eye drops in children 2 years of age and older. However, safety and efficacy have not been established in children younger than 2 years of age.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific ...